Andere Sprachen InMed Pharmaceuticals Inc.

Aktien

A3DTK2

CA4576376012

INM

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.04.2024			% 5 Tage	% 1. Jan.
0.3 ^USD	-1.78%		-18.92%	-27.88%

04.04.	InMed Pharmaceuticals Inc. gibt zusätzliche präklinische Daten bekannt, die die positiven pharmakologischen Wirkungen von INM-901 bei der potenziellen Behandlung der Alzheimer-Krankheit belegen	CI
13.02.	InMed Pharmaceuticals Inc. gibt Update zu pharmazeutischen Entwicklungsprogrammen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration	16.04.
InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease	04.04.
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies	04.04.
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance	20.03.
InMed Pharmaceuticals Inc. Provides Update on Pharmaceutical Development Programs	13.02.
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update	13.02.
InMed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13.02.
InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024	09.02.
InMed Pharmaceuticals Inc. Announces Executive Changes, Effective February 20, 2024	09.02.
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer	09.02.
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET	18.01.
InMed Pharmaceuticals Provides Business Update and Milestones for 2024	16.01.
InMed Announces Results of 2023 Annual General Meeting	20.12.
Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089	29.11.
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration	29.11.
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update	14.11.
InMed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14.11.
InMed Pharmaceuticals Inc. Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch 2023	02.11.
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023	02.11.
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules	27.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen InMed Pharmaceuticals Inc.

Aktien

A3DTK2

CA4576376012

INM

Andere Sprachen

Filter